AiCurator
Clinical site dashboards for trial monitoring and participant management
Software · Cloud SaaSCompany source
Company profile
About AiCure
AiCure is a leading AI and advanced data analytics company specializing in clinical trial optimization through its flagship platform, H.Code. The company has pioneered AI-powered adherence verification technology trusted by pharmaceutical companies, contract research organizations (CROs), and healthcare providers to verify medication and clinical behavior adherence across the healthcare lifecycle. H.Code combines AI-powered computer vision, synchronous chat, and predictive analytics to remotely observe and assist trial participants through their smartphones, revolutionizing access and participation while improving statistical power and deepening understanding of the relationship between patient behavior and trial outcomes. The platform supports all types of clinical trials—traditional site-based, decentralized, fully virtual, or hybrid models—across any therapeutic indication. AiCure's technology has been deployed across more than 2,200 clinical trial sites in 46 countries, capturing over 1.5 million participant doses with a 92% participant retention rate. The company's research demonstrates that early medication adherence captured through H.Code can serve as a marker for participant retention, with their Clinical Site Services framework reducing early termination rates for adherent participants to just 7.8% across 28 phase I-IV clinical trials. AiCure serves seven of the top 10 global pharmaceutical companies and has been awarded 84 patents for its innovative approach to clinical trial patient engagement and adherence monitoring.
Company description AiCure official website
Primary marketClinical Trials & Research
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at AiCure?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Alzheimer's disease
- Autism
- Depression
- Hepatitis C
- HIV
- Neurodegenerative diseases
- Parkinson's disease
- Schizophrenia
Who it serves
- Clinical trial sites
- Contract Research Organizations (CROs)
- Healthcare providers
- Pharmaceutical companies
Deployment & integration
Cloud Saas · Hybrid deployment with recorded integration context.
Recorded integration context: Additional patient data sources, Clinical workflows and records, Patient companion apps.
Geographic context
Markets46 countries · Global deployment
Company sourceOfficial website
Company milestones
Platform expansion
Over 2,200 clinical trial sites deployed, 1.5+ million participant doses captured, 84 patents awarded, research published on early termination prediction
Partnerships
Recorded partners
- 7 of top 10 global pharmaceutical companies
- Abbvie
- Cerevel Therapeutics
- Sage Therapeutics
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Clinical Site Services (CSS)
Tech-enabled operational monitoring framework to reduce early termination
Service · HybridCompany source
Digital Phenotypes
Audio and visual digital biomarker detection for treatment response monitoring
Software · Cloud SaaSCompany source
H.Code
AI-powered adherence verification platform for clinical trials and healthcare
Platform · Cloud SaaSCompany source
Patient Connect
Mobile app for real-time medication adherence and remote patient monitoring
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
AI-based medication adherence prediction in patients with schizophrenia and attenuated psychotic disorders.Schizophrenia research · Jan 1, 2025
Acceptability of an automated directly observed therapy (DOT) application for PrEP adherence support among young men who have sex with men: a qualitative exploration.AIDS care · Nov 1, 2024
Identifying Unmet Needs in Major Depressive Disorder Using a Computer-Assisted Alternative to Conventional Thematic Analysis: Qualitative Interview Study With Psychiatrists.JMIR formative research · Mar 1, 2024
Randomized Controlled Trial of Automated Directly Observed Therapy for Measurement and Support of PrEP Adherence Among Young Men Who have Sex with Men.AIDS and behavior · Feb 1, 2023
Opportunities for digital health technology: identifying unmet needs for bipolar misdiagnosis and depression care management.Frontiers in digital health · Jan 1, 2023
Characterizing clinical pediatric obesity subtypes using electronic health record data.PLOS digital health · Aug 1, 2022
Clinical validation
Clinical-trial records
DOT Diary Mobile App for Pre-Exposure Prophylaxis Adherence in Young MenNCT03771638 · Sponsor · COMPLETED
Youth Ending the HIV EpidemicNCT05789875 · Sponsor · COMPLETED
DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP AdherenceNCT03387462 · Sponsor · COMPLETED
Smartphone Based aDOT Treatment With Fixed-Dose Elbasvir and Grazoprevir in PWIDsNCT03127358 · Sponsor · COMPLETED
Using Artificial Intelligence To Monitor Medication Adherence in Opioid Replacement TherapyNCT02243670 · Sponsor · COMPLETED
Using Artificial Intelligence to Measure and Optimize Adherence in Patients on Anticoagulation Therapy.NCT02599259 · Sponsor · COMPLETED
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
92% participant retention rate
Across clinical trials using H.Code platform
1.5+ million participant doses captured
Total doses verified through platform
7.8% early termination rate
For adherent participants across 28 phase I-IV trials with 4,000+ patients
50%+ reduction in dropout rates
Reported by Abbvie - dropout rates cut by more than half
Abbvie
Reducing participant dropout rates in clinical trials
Drop-out rates cut down by more than half
Cerevel Therapeutics
Advanced facial recognition and mapping for detecting subtle clinical changes
Most advanced in facial recognition and mapping software for clinical detection
Multiple Pharma Companies
Reducing early termination in clinical trials through tech-enabled monitoring
Early termination rates reduced to 7.8% for adherent participants across 28 phase I-IV trials with 4,000+ patients in 43 countries
Sage Therapeutics
Using AiCure as an active data collection tool to drive clinical action
Shifted from passive data collection to action-driving tool
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Matthew Leoni
VP, Global Clinical Development
Sarah Titus
Director of Clinical Operations & Development
Kyle Holen
Head of Development Design Center
06 · Company updates
Updates from AiCure
Recent articles published on AiCure's official website.
AICure Expands Executive Leadership to Accelerate AI-Powered Medication Adherence, Remote Weight Verification, and Enterprise White-Label Solutions
Read on AiCureForbes: The AI Company Transforming Medication Adherence And Weight Loss
Read on AiCureAiCure Appoints Sabina Chadha as CEO, Ed Ikeguchi Transitions to Chief Medical Officer, and Josh Wilson Promoted to COO and President
Read on AiCureClinical Research, Inequality and the Future of Women’s Health
Read on AiCureFrom Guidelines to Standards: Why Comprehensive AI Regulation is Essential to Spurring Innovation
Read on AiCure07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Clinical Trials & Research
Companies using AI to optimize clinical trial design, accelerate patient recruitment, match patients to trials, predict trial outcomes, or improve clinical research efficiency. Includes patient enrollment and screening platforms, AI-powered trial matching, and tools that reduce the time and cost of bringing new treatments to market.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.